A Food and Drug Administration official recommended approving puberty blockers for youth with gender dysphoria while acknowledging that a study showed the drugs were associated with an “increased risk in depression and suicidality,” according to internal emails released by America First Legal.
Sharon Sullivan, the clinical team leader at the FDA’s Division of General Endocrinology, in January 2022 wrote in an email to her supervisor: “There is definitely a need for these drugs to be approved for gender transition, as they are typically not covered by insurance and are expensive out of pocket.
“We found no effect on bone (after factoring in catch-up growth), including no increase in fracture risk. We did find increased risk of depression and suicidality, as well as increased seizure risk and we issued” safety-related labeling changes, she wrote.
Read more at Newsmax© 2024 Newsmax. All rights reserved.
